Daxor Corporation
Daxor Corporation (DXR) Stock Competitors & Peer Comparison
See (DXR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $11.00 | +1.50% | 54.6M | -122.22 | -$0.09 | N/A |
| ISRG | $476.16 | +1.34% | 170.7B | 66.50 | $7.16 | N/A |
| BDX | $199.66 | +1.54% | 57.2B | 36.51 | $5.47 | +2.04% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.04% |
| RMD | $293.73 | +1.87% | 43B | 30.89 | $9.51 | +0.75% |
| ALC | $82.02 | +3.59% | 40.5B | 37.95 | $2.16 | +0.41% |
| WST | $247.85 | +2.15% | 17.8B | 37.18 | $6.67 | +0.34% |
| HOLX | $68.26 | +1.62% | 15.2B | 28.32 | $2.41 | N/A |
| COO | $75.22 | +2.98% | 15B | 36.34 | $2.07 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.04% |
Stock Comparison
DXR vs ISRG Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ISRG has a market cap of 170.7B. Regarding current trading prices, DXR is priced at $11.00, while ISRG trades at $476.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ISRG's P/E ratio is 66.50. In terms of profitability, DXR's ROE is +0.02%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, DXR is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ISRG's competition here
DXR vs BDX Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, BDX has a market cap of 57.2B. Regarding current trading prices, DXR is priced at $11.00, while BDX trades at $199.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas BDX's P/E ratio is 36.51. In terms of profitability, DXR's ROE is +0.02%, compared to BDX's ROE of +0.06%. Regarding short-term risk, DXR is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
DXR vs BDXA Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $11.00, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas BDXA's P/E ratio is 21.44. In terms of profitability, DXR's ROE is +0.02%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, DXR is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
DXR vs RMD Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, RMD has a market cap of 43B. Regarding current trading prices, DXR is priced at $11.00, while RMD trades at $293.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas RMD's P/E ratio is 30.89. In terms of profitability, DXR's ROE is +0.02%, compared to RMD's ROE of +0.26%. Regarding short-term risk, DXR is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check RMD's competition here
DXR vs ALC Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ALC has a market cap of 40.5B. Regarding current trading prices, DXR is priced at $11.00, while ALC trades at $82.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ALC's P/E ratio is 37.95. In terms of profitability, DXR's ROE is +0.02%, compared to ALC's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ALC's competition here
DXR vs WST Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, WST has a market cap of 17.8B. Regarding current trading prices, DXR is priced at $11.00, while WST trades at $247.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas WST's P/E ratio is 37.18. In terms of profitability, DXR's ROE is +0.02%, compared to WST's ROE of +0.18%. Regarding short-term risk, DXR is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check WST's competition here
DXR vs HOLX Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, HOLX has a market cap of 15.2B. Regarding current trading prices, DXR is priced at $11.00, while HOLX trades at $68.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas HOLX's P/E ratio is 28.32. In terms of profitability, DXR's ROE is +0.02%, compared to HOLX's ROE of +0.12%. Regarding short-term risk, DXR is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HOLX's competition here
DXR vs COO Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, COO has a market cap of 15B. Regarding current trading prices, DXR is priced at $11.00, while COO trades at $75.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas COO's P/E ratio is 36.34. In terms of profitability, DXR's ROE is +0.02%, compared to COO's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check COO's competition here
DXR vs BDXB Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $11.00, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.02%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, DXR is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
DXR vs BAX Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, BAX has a market cap of 12.6B. Regarding current trading prices, DXR is priced at $11.00, while BAX trades at $24.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas BAX's P/E ratio is -51.09. In terms of profitability, DXR's ROE is +0.02%, compared to BAX's ROE of -0.02%. Regarding short-term risk, DXR is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
DXR vs ATR Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ATR has a market cap of 9.3B. Regarding current trading prices, DXR is priced at $11.00, while ATR trades at $141.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ATR's P/E ratio is 24.42. In terms of profitability, DXR's ROE is +0.02%, compared to ATR's ROE of +0.15%. Regarding short-term risk, DXR is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
DXR vs MASI Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, MASI has a market cap of 8.1B. Regarding current trading prices, DXR is priced at $11.00, while MASI trades at $148.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas MASI's P/E ratio is -29.26. In terms of profitability, DXR's ROE is +0.02%, compared to MASI's ROE of -0.41%. Regarding short-term risk, DXR is less volatile compared to MASI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MASI's competition here
DXR vs RGEN Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, RGEN has a market cap of 7B. Regarding current trading prices, DXR is priced at $11.00, while RGEN trades at $124.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas RGEN's P/E ratio is -499.16. In terms of profitability, DXR's ROE is +0.02%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, DXR is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
DXR vs STVN Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, STVN has a market cap of 6.2B. Regarding current trading prices, DXR is priced at $11.00, while STVN trades at $22.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas STVN's P/E ratio is 39.63. In terms of profitability, DXR's ROE is +0.02%, compared to STVN's ROE of +0.10%. Regarding short-term risk, DXR is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
DXR vs TFX Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, DXR is priced at $11.00, while TFX trades at $129.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas TFX's P/E ratio is 30.26. In terms of profitability, DXR's ROE is +0.02%, compared to TFX's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
DXR vs MMSI Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, MMSI has a market cap of 5.3B. Regarding current trading prices, DXR is priced at $11.00, while MMSI trades at $89.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas MMSI's P/E ratio is 45.41. In terms of profitability, DXR's ROE is +0.02%, compared to MMSI's ROE of +0.08%. Regarding short-term risk, DXR is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
DXR vs BLCO Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, BLCO has a market cap of 5.3B. Regarding current trading prices, DXR is priced at $11.00, while BLCO trades at $14.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas BLCO's P/E ratio is -19.13. In terms of profitability, DXR's ROE is +0.02%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, DXR is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
DXR vs WRBY Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, WRBY has a market cap of 3.3B. Regarding current trading prices, DXR is priced at $11.00, while WRBY trades at $27.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas WRBY's P/E ratio is -338.07. In terms of profitability, DXR's ROE is +0.02%, compared to WRBY's ROE of -0.03%. Regarding short-term risk, DXR is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check WRBY's competition here
DXR vs ICUI Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ICUI has a market cap of 3.2B. Regarding current trading prices, DXR is priced at $11.00, while ICUI trades at $128.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ICUI's P/E ratio is -84.33. In terms of profitability, DXR's ROE is +0.02%, compared to ICUI's ROE of -0.02%. Regarding short-term risk, DXR is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
DXR vs XRAY Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, XRAY has a market cap of 2.9B. Regarding current trading prices, DXR is priced at $11.00, while XRAY trades at $14.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas XRAY's P/E ratio is -3.13. In terms of profitability, DXR's ROE is +0.02%, compared to XRAY's ROE of -0.45%. Regarding short-term risk, DXR is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
DXR vs HAE Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, HAE has a market cap of 2.7B. Regarding current trading prices, DXR is priced at $11.00, while HAE trades at $56.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas HAE's P/E ratio is 17.22. In terms of profitability, DXR's ROE is +0.02%, compared to HAE's ROE of +0.19%. Regarding short-term risk, DXR is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check HAE's competition here
DXR vs LMAT Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, LMAT has a market cap of 2.3B. Regarding current trading prices, DXR is priced at $11.00, while LMAT trades at $100.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas LMAT's P/E ratio is 48.94. In terms of profitability, DXR's ROE is +0.02%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
DXR vs NNNN Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, NNNN has a market cap of 2.2B. Regarding current trading prices, DXR is priced at $11.00, while NNNN trades at $49.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas NNNN's P/E ratio is 997.20. In terms of profitability, DXR's ROE is +0.02%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
DXR vs QDEL Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, QDEL has a market cap of 1.9B. Regarding current trading prices, DXR is priced at $11.00, while QDEL trades at $27.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas QDEL's P/E ratio is -4.08. In terms of profitability, DXR's ROE is +0.02%, compared to QDEL's ROE of -0.16%. Regarding short-term risk, DXR is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check QDEL's competition here
DXR vs ATRC Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ATRC has a market cap of 1.9B. Regarding current trading prices, DXR is priced at $11.00, while ATRC trades at $37.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ATRC's P/E ratio is -48.91. In terms of profitability, DXR's ROE is +0.02%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, DXR is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
DXR vs AZTA Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, AZTA has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $11.00, while AZTA trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas AZTA's P/E ratio is -9.72. In terms of profitability, DXR's ROE is +0.02%, compared to AZTA's ROE of -0.07%. Regarding short-term risk, DXR is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
DXR vs NVCR Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, NVCR has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $11.00, while NVCR trades at $12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas NVCR's P/E ratio is -7.97. In terms of profitability, DXR's ROE is +0.02%, compared to NVCR's ROE of -0.48%. Regarding short-term risk, DXR is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NVCR's competition here
DXR vs STAA Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, STAA has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $11.00, while STAA trades at $27.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas STAA's P/E ratio is -14.43. In terms of profitability, DXR's ROE is +0.02%, compared to STAA's ROE of -0.25%. Regarding short-term risk, DXR is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
DXR vs BLFS Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, BLFS has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $11.00, while BLFS trades at $25.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas BLFS's P/E ratio is -64.77. In terms of profitability, DXR's ROE is +0.02%, compared to BLFS's ROE of -0.02%. Regarding short-term risk, DXR is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
DXR vs PLSE Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, PLSE has a market cap of 1.1B. Regarding current trading prices, DXR is priced at $11.00, while PLSE trades at $17.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas PLSE's P/E ratio is -15.79. In terms of profitability, DXR's ROE is +0.02%, compared to PLSE's ROE of -0.65%. Regarding short-term risk, DXR is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
DXR vs KMTS Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, KMTS has a market cap of 953.8M. Regarding current trading prices, DXR is priced at $11.00, while KMTS trades at $18.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas KMTS's P/E ratio is -3.62. In terms of profitability, DXR's ROE is +0.02%, compared to KMTS's ROE of +0.72%. Regarding short-term risk, DXR is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
DXR vs ATRI Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $11.00, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.02%, compared to ATRI's ROE of +0.01%. Regarding short-term risk, DXR is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
DXR vs ANGO Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ANGO has a market cap of 384M. Regarding current trading prices, DXR is priced at $11.00, while ANGO trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ANGO's P/E ratio is -11.39. In terms of profitability, DXR's ROE is +0.02%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, DXR is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
DXR vs SMTI Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, SMTI has a market cap of 302.2M. Regarding current trading prices, DXR is priced at $11.00, while SMTI trades at $33.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas SMTI's P/E ratio is -29.27. In terms of profitability, DXR's ROE is +0.02%, compared to SMTI's ROE of -0.26%. Regarding short-term risk, DXR is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
DXR vs STXS Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, STXS has a market cap of 262.4M. Regarding current trading prices, DXR is priced at $11.00, while STXS trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas STXS's P/E ratio is -10.00. In terms of profitability, DXR's ROE is +0.02%, compared to STXS's ROE of -2.19%. Regarding short-term risk, DXR is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STXS's competition here
DXR vs NYXH Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, NYXH has a market cap of 240.7M. Regarding current trading prices, DXR is priced at $11.00, while NYXH trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas NYXH's P/E ratio is -2.61. In terms of profitability, DXR's ROE is +0.02%, compared to NYXH's ROE of -0.65%. Regarding short-term risk, DXR is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NYXH's competition here
DXR vs OSUR Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, OSUR has a market cap of 219.4M. Regarding current trading prices, DXR is priced at $11.00, while OSUR trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas OSUR's P/E ratio is -4.41. In terms of profitability, DXR's ROE is +0.02%, compared to OSUR's ROE of -0.13%. Regarding short-term risk, DXR is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
DXR vs KRMD Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, KRMD has a market cap of 202.5M. Regarding current trading prices, DXR is priced at $11.00, while KRMD trades at $4.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas KRMD's P/E ratio is -43.80. In terms of profitability, DXR's ROE is +0.02%, compared to KRMD's ROE of -0.27%. Regarding short-term risk, DXR is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
DXR vs UTMD Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, UTMD has a market cap of 195.4M. Regarding current trading prices, DXR is priced at $11.00, while UTMD trades at $60.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas UTMD's P/E ratio is 16.25. In terms of profitability, DXR's ROE is +0.02%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, DXR is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
DXR vs INFU Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, INFU has a market cap of 195.1M. Regarding current trading prices, DXR is priced at $11.00, while INFU trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas INFU's P/E ratio is 39.79. In terms of profitability, DXR's ROE is +0.02%, compared to INFU's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check INFU's competition here
DXR vs MBOT Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, MBOT has a market cap of 175.4M. Regarding current trading prices, DXR is priced at $11.00, while MBOT trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas MBOT's P/E ratio is -6.64. In terms of profitability, DXR's ROE is +0.02%, compared to MBOT's ROE of -0.76%. Regarding short-term risk, DXR is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MBOT's competition here
DXR vs PDEX Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, PDEX has a market cap of 150.1M. Regarding current trading prices, DXR is priced at $11.00, while PDEX trades at $46.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas PDEX's P/E ratio is 16.68. In terms of profitability, DXR's ROE is +0.02%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, DXR is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
DXR vs ZJYL Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ZJYL has a market cap of 113.3M. Regarding current trading prices, DXR is priced at $11.00, while ZJYL trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ZJYL's P/E ratio is 36.20. In terms of profitability, DXR's ROE is +0.02%, compared to ZJYL's ROE of +0.10%. Regarding short-term risk, DXR is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
DXR vs ZTEK Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ZTEK has a market cap of 71.7M. Regarding current trading prices, DXR is priced at $11.00, while ZTEK trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ZTEK's P/E ratio is -11.42. In terms of profitability, DXR's ROE is +0.02%, compared to ZTEK's ROE of -0.59%. Regarding short-term risk, DXR is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ZTEK's competition here
DXR vs AKYA Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $11.00, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.02%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, DXR is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check AKYA's competition here
DXR vs OMIC Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $11.00, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.02%, compared to OMIC's ROE of -0.45%. Regarding short-term risk, DXR is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
DXR vs IGAP Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $11.00, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.02%, compared to IGAP's ROE of -20.88%. Regarding short-term risk, DXR is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
DXR vs WOK Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, WOK has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $11.00, while WOK trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas WOK's P/E ratio is -2.90. In terms of profitability, DXR's ROE is +0.02%, compared to WOK's ROE of -0.30%. Regarding short-term risk, DXR is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check WOK's competition here
DXR vs MLSS Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, MLSS has a market cap of 47.1M. Regarding current trading prices, DXR is priced at $11.00, while MLSS trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas MLSS's P/E ratio is -7.50. In terms of profitability, DXR's ROE is +0.02%, compared to MLSS's ROE of -1.34%. Regarding short-term risk, DXR is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
DXR vs NEPH Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, NEPH has a market cap of 44.3M. Regarding current trading prices, DXR is priced at $11.00, while NEPH trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas NEPH's P/E ratio is 34.83. In terms of profitability, DXR's ROE is +0.02%, compared to NEPH's ROE of +0.15%. Regarding short-term risk, DXR is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
DXR vs POCI Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, POCI has a market cap of 37.1M. Regarding current trading prices, DXR is priced at $11.00, while POCI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas POCI's P/E ratio is -5.31. In terms of profitability, DXR's ROE is +0.02%, compared to POCI's ROE of -0.54%. Regarding short-term risk, DXR is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
DXR vs SDC Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $11.00, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.02%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
DXR vs NXGL Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, NXGL has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $11.00, while NXGL trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas NXGL's P/E ratio is -5.85. In terms of profitability, DXR's ROE is +0.02%, compared to NXGL's ROE of -0.57%. Regarding short-term risk, DXR is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
DXR vs IVC Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $11.00, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.02%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
DXR vs RVP Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, RVP has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $11.00, while RVP trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas RVP's P/E ratio is -2.77. In terms of profitability, DXR's ROE is +0.02%, compared to RVP's ROE of -0.11%. Regarding short-term risk, DXR is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
DXR vs NXGLW Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, NXGLW has a market cap of 23.3M. Regarding current trading prices, DXR is priced at $11.00, while NXGLW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas NXGLW's P/E ratio is -0.22. In terms of profitability, DXR's ROE is +0.02%, compared to NXGLW's ROE of -0.57%. Regarding short-term risk, DXR is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NXGLW's competition here
DXR vs HBIO Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, HBIO has a market cap of 21.8M. Regarding current trading prices, DXR is priced at $11.00, while HBIO trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas HBIO's P/E ratio is -0.38. In terms of profitability, DXR's ROE is +0.02%, compared to HBIO's ROE of -1.60%. Regarding short-term risk, DXR is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
DXR vs FEMY Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, FEMY has a market cap of 18.3M. Regarding current trading prices, DXR is priced at $11.00, while FEMY trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas FEMY's P/E ratio is -0.65. In terms of profitability, DXR's ROE is +0.02%, compared to FEMY's ROE of -7.14%. Regarding short-term risk, DXR is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
DXR vs MHUA Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, MHUA has a market cap of 12.9M. Regarding current trading prices, DXR is priced at $11.00, while MHUA trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas MHUA's P/E ratio is 1.01. In terms of profitability, DXR's ROE is +0.02%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MHUA's competition here
DXR vs POAI Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, POAI has a market cap of 10.1M. Regarding current trading prices, DXR is priced at $11.00, while POAI trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas POAI's P/E ratio is -0.82. In terms of profitability, DXR's ROE is +0.02%, compared to POAI's ROE of +1122.67%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
DXR vs EKSO Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, EKSO has a market cap of 9.3M. Regarding current trading prices, DXR is priced at $11.00, while EKSO trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas EKSO's P/E ratio is -0.55. In terms of profitability, DXR's ROE is +0.02%, compared to EKSO's ROE of -0.87%. Regarding short-term risk, DXR is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check EKSO's competition here
DXR vs LUCY Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, LUCY has a market cap of 9.1M. Regarding current trading prices, DXR is priced at $11.00, while LUCY trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas LUCY's P/E ratio is -0.91. In terms of profitability, DXR's ROE is +0.02%, compared to LUCY's ROE of -184.00%. Regarding short-term risk, DXR is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
DXR vs STSS Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, STSS has a market cap of 7.5M. Regarding current trading prices, DXR is priced at $11.00, while STSS trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas STSS's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.02%, compared to STSS's ROE of -0.09%. Regarding short-term risk, DXR is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
DXR vs LUCYW Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, LUCYW has a market cap of 6.8M. Regarding current trading prices, DXR is priced at $11.00, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas LUCYW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to LUCYW's ROE of -184.00%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
DXR vs NSTG Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $11.00, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.02%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
DXR vs GCTK Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, GCTK has a market cap of 3.1M. Regarding current trading prices, DXR is priced at $11.00, while GCTK trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas GCTK's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to GCTK's ROE of +18.17%. Regarding short-term risk, DXR is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GCTK's competition here
DXR vs GMVD Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $11.00, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.02%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
DXR vs GMVDW Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $11.00, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
DXR vs AVGR Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $11.00, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.02%, compared to AVGR's ROE of -5.38%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
DXR vs IIN Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $11.00, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.02%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IIN's competition here
DXR vs LMNX Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, LMNX has a market cap of 0. Regarding current trading prices, DXR is priced at $11.00, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas LMNX's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, DXR is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check LMNX's competition here
DXR vs ATRS Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $11.00, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.02%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here
DXR vs HRC Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $11.00, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.02%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HRC's competition here
DXR vs APR Comparison August 2025
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.6M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $11.00, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -122.22, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.02%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check APR's competition here